← Back to Search

Anti-VEGF Monoclonal Antibody

EYP-1901 for Wet Age-Related Macular Degeneration (DAVIO2 Trial)

Phase 2
Waitlist Available
Research Sponsored by EyePoint Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented diagnosis of wAMD in the study eye, with disease onset any time prior to the Screening Visit
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 28 and week 32
Awards & highlights

DAVIO2 Trial Summary

This trial is testing a new drug, EYP-1901, to see if it is better than Aflibercept at treating wet age-related macular degeneration.

Who is the study for?
This trial is for people with wet Age-Related Macular Degeneration (wAMD) who have had at least two anti-VEGF injections in the past 6 months. Participants should have a certain level of vision, ranging from 20/200 to 20/20 Snellen equivalent. Those with eye thickness over a specific limit or other eye conditions like cataracts or glaucoma, or any history of inflammation besides routine cataract surgery are excluded.Check my eligibility
What is being tested?
The study compares two doses of EYP-1901 (2060 ug and 3090 ug) against Aflibercept to see which is more effective for wAMD. It's a phase 2 trial where participants are randomly assigned to receive one treatment and neither they nor the researchers know who gets which dose.See study design
What are the potential side effects?
Potential side effects may include typical reactions related to intravitreal injections such as eye redness, discomfort, or infection risk. Specific side effects related to EYP-1901 aren't detailed but could be similar to those observed with other anti-VEGF treatments.

DAVIO2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with wet age-related macular degeneration in one eye.

DAVIO2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 28 and week 32
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 28 and week 32 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average change in best corrected visual acuity (BCVA)
Secondary outcome measures
Change in best corrected visual acuity (BCVA)
Tomography, Optical Coherence
Number of rescue injections

Side effects data

From 2020 Phase 4 trial • 26 Patients • NCT03022292
4%
Retinal detachment
4%
Myelodysplastic syndrome
4%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
IAI Treatment

DAVIO2 Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: EYP-1901 3090 ugExperimental Treatment1 Intervention
EYP-1901 3090 ug, single dose
Group II: EYP-1901 2060 ugExperimental Treatment1 Intervention
EYP-1901 2060 ug, single dose
Group III: AfliberceptActive Control1 Intervention
Aflibercept 2 mg [0.05mL] every 8 weeks

Find a Location

Who is running the clinical trial?

EyePoint Pharmaceuticals, Inc.Lead Sponsor
16 Previous Clinical Trials
1,771 Total Patients Enrolled

Media Library

Aflibercept (Anti-VEGF Monoclonal Antibody) Clinical Trial Eligibility Overview. Trial Name: NCT05381948 — Phase 2
Age-Related Macular Degeneration Research Study Groups: EYP-1901 2060 ug, EYP-1901 3090 ug, Aflibercept
Age-Related Macular Degeneration Clinical Trial 2023: Aflibercept Highlights & Side Effects. Trial Name: NCT05381948 — Phase 2
Aflibercept (Anti-VEGF Monoclonal Antibody) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05381948 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of participants being recruited for this trial?

"Indeed, the clinical trial is still actively recruiting. The study was first advertised on 28th July 2022 and modified 18th August 2022. 150 patients need to be enrolled from 4 different research centres."

Answered by AI

Has Eyp-1901 received approval from the U.S. Food and Drug Administration?

"Due to limited clinical evidence of efficacy, Eyp-1901 was assigned a safety rating of 2. Nonetheless, there is some data confirming its security profile."

Answered by AI

Are there numerous healthcare facilities in North America conducting this experiment?

"This experiment is currently being conducted at 4 distinct medical centres situated in Austin, Dallas and San Antonio amongst others. To make the process more convenient for participants, it's recommended to pick a clinic close by."

Answered by AI

Are individuals still eligible to volunteer for this experiment?

"Indeed, the clinicaltrials.gov website implies that this trial is presently looking for volunteers. Having first been uploaded on July 28th 2022, it has recently undergone a revision and seeks to enrol 150 participants from 4 sites."

Answered by AI
~60 spots leftby Mar 2025